See more : Zhejiang Huahai Pharmaceutical Co., Ltd. (600521.SS) Income Statement Analysis – Financial Results
Complete financial analysis of Vivani Medical, Inc. (VANI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vivani Medical, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Nova Royalty Corp. (NOVRF) Income Statement Analysis – Financial Results
- JMC Electronics Co., Ltd. (6552.TW) Income Statement Analysis – Financial Results
- Alkyl Amines Chemicals Limited (ALKYLAMINE.BO) Income Statement Analysis – Financial Results
- Mallinckrodt plc (MNKKQ) Income Statement Analysis – Financial Results
- Sunshine Capital Limited (SCL.BO) Income Statement Analysis – Financial Results
Vivani Medical, Inc. (VANI)
About Vivani Medical, Inc.
Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 3.38M | 6.90M | 7.96M | 3.99M | 8.95M | 3.40M | 1.56M | 1.37M |
| Cost of Revenue | 357.00K | 381.00K | 345.00K | 167.00K | 2.15M | 4.89M | 7.75M | 9.35M | 4.30M | 3.56M | 5.63M | 4.40M |
| Gross Profit | -357.00K | -381.00K | -345.00K | -167.00K | 1.23M | 2.01M | 211.00K | -5.36M | 4.65M | -160.28K | -4.06M | -3.03M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 36.31% | 29.12% | 2.65% | -134.60% | 51.93% | -4.72% | -259.72% | -221.58% |
| Research & Development | 16.97M | 14.17M | 11.00M | 6.87M | 16.50M | 10.21M | 7.99M | 5.35M | 3.04M | 5.04M | 3.25M | 3.05M |
| General & Administrative | 10.00M | 7.07M | 2.32M | 2.38M | 9.23M | 10.69M | 10.93M | 10.08M | 8.22M | 6.57M | 4.17M | 4.03M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 6.10M | 11.34M | 9.57M | 8.99M | 8.94M | 6.84M | 3.30M | 2.19M |
| SG&A | 10.00M | 7.07M | 2.32M | 2.38M | 15.33M | 26.63M | 23.56M | 21.77M | 20.67M | 13.41M | 7.47M | 6.22M |
| Other Expenses | 0.00 | 475.00K | -91.00K | -36.00K | 3.35M | 4.60M | 2.64M | -727.00K | -991.00K | 2.62M | 3.22M | 3.73M |
| Operating Expenses | 26.97M | 21.24M | 13.32M | 9.24M | 31.82M | 36.83M | 28.92M | 27.85M | 24.70M | 21.07M | 13.93M | 12.99M |
| Cost & Expenses | 26.97M | 21.24M | 13.32M | 9.24M | 33.98M | 41.72M | 36.67M | 37.20M | 29.00M | 24.63M | 19.56M | 17.39M |
| Interest Income | 0.00 | 0.00 | 0.00 | 16.00K | 362.00K | 86.00K | 93.00K | 31.00K | 2.00K | 9.11K | 7.45K | 7.51K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 29.00K | 7.03M | 5.01M | 267.03K |
| Depreciation & Amortization | 357.00K | 381.00K | 345.00K | 167.00K | 414.00K | 435.00K | 457.00K | 432.00K | 335.00K | 279.18K | 315.77K | 324.71K |
| EBITDA | -26.61M | -19.16M | -12.98M | -8.89M | -33.18M | -34.66M | -28.06M | -32.75M | -19.68M | -27.89M | -17.64M | -15.69M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -893.25% | -498.69% | -354.75% | -822.53% | -220.25% | -820.75% | -1,127.18% | -1,147.39% |
| Operating Income | -26.97M | -21.24M | -13.32M | -9.24M | -30.60M | -34.83M | -28.71M | -33.21M | -20.05M | -21.23M | -18.00M | -16.02M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -905.50% | -505.00% | -360.48% | -833.38% | -223.99% | -624.91% | -1,150.05% | -1,171.82% |
| Total Other Income/Expenses | 1.31M | 7.35M | 550.00K | -36.00K | -3.00M | -269.00K | 193.00K | 31.00K | 29.00K | -13.97M | -4.97M | -257.74K |
| Income Before Tax | -25.65M | -13.89M | -12.77M | -9.28M | -33.59M | -35.09M | -28.52M | -33.18M | -20.02M | -35.20M | -22.97M | -16.28M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -994.14% | -508.90% | -358.06% | -832.60% | -223.66% | -1,035.99% | -1,467.73% | -1,190.67% |
| Income Tax Expense | 0.00 | -7.35M | -641.00K | 147.70K | 362.00K | 86.00K | 93.00K | 31.00K | 58.00K | -6.93M | 42.22K | 9.29K |
| Net Income | -25.65M | -6.54M | -12.13M | -9.28M | -33.59M | -35.09M | -28.52M | -33.18M | -20.02M | -35.20M | -22.97M | -16.28M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -994.14% | -508.90% | -358.06% | -832.60% | -223.66% | -1,035.99% | -1,467.73% | -1,190.67% |
| EPS | -0.50 | -0.17 | -1.10 | -1.35 | -6.85 | -12.69 | -12.64 | -20.13 | -13.48 | -10.31 | -4.87 | -3.45 |
| EPS Diluted | -0.50 | -0.17 | -1.10 | -1.35 | -6.85 | -12.69 | -12.64 | -20.13 | -13.48 | -10.31 | -4.87 | -3.45 |
| Weighted Avg Shares Out | 50.85M | 38.24M | 11.03M | 6.86M | 4.90M | 2.77M | 2.26M | 1.65M | 1.48M | 3.41M | 4.72M | 4.72M |
| Weighted Avg Shares Out (Dil) | 50.85M | 38.24M | 11.03M | 6.86M | 4.90M | 2.77M | 2.26M | 1.65M | 1.48M | 3.41M | 4.72M | 4.72M |
Vivani Medical to Present at the Innovation in Obesity Therapeutics Summit West Coast
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative biopharmaceutical company developing miniaturized, ultra long-acting drug implants, announced today that CEO Adam Mendelsohn, Ph.D., will present and participate in a panel discussion at the Innovation in...
Vivani Medical Receives Regulatory Approval to Initiate First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative, biopharmaceutical company developing novel, ultra long-acting drug implants, today announced that the Bellberry Human Research Ethics Committee (“HREC”) has approved and the Therapeutic Goods Administration (“TGA”) in...
Vivani Medical to Present at the Emerging Growth Conference on September 25, 2024
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative biopharmaceutical company developing miniaturized, ultra long-acting drug implants, announced today that it will present at the Emerging Growth Conference on September 25, 2024. Vivani invites individual and...
Vivani Medical to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative biopharmaceutical company developing miniature, ultra long-acting, subdermal drug implants, today announced its plans to participate in the H.C. Wainwright 26th Annual Global Investment Conference taking place September...
Vivani Medical Announces FDA Clears Investigational New Drug Application and Lifts Clinical Hold for NPM-119, a Miniature Long-Term Subdermal GLP-1 Drug Implant
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative, biopharmaceutical company developing novel, long-term drug implants, today announced the U.S. Food and Drug Administration has cleared the Investigational New Drug Application (“IND”) and lifted the clinical...
Vivani Medical Announces Publication of Positive Weight Loss Data Supporting Potential Veterinary Use of OKV-119 Miniature, Long-term GLP-1 Implant
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company developing miniaturized, long-term drug implants including its lead asset NPM-115 for chronic weight management in obese or overweight human patients with one or more risk factors,...
VANI Stock Earnings: Vivani Medical Meets EPS for Q1 2024
Vivani Medical (NASDAQ: VANI ) just reported results for the first quarter of 2024. Vivani Medical reported earnings per share of -12 cents.
Vivani Medical Provides Business Update and Reports First Quarter 2024 Financial Results
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company developing miniaturized, long-term drug implants including its lead asset NPM-115 for chronic weight management in obese or overweight patients with one or more risk factors, today...
Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company developing miniaturized, long-term drug implants including its lead asset NPM-115 for chronic weight management in obese or overweight patients with one or more risk factors, today...
Vivani Medical Appoints Daniel Bradbury to its Board of Directors
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative, preclinical-stage biopharmaceutical company developing novel, long-term drug implants, today announced the appointment of long-time industry veteran Daniel Bradbury to its Board of Directors. “Dan has served as...
Source: https://incomestatements.info
Category: Stock Reports